ES2080452T3 - Uso de bifosfonatos para la fabricacion de un medicamento para el bloqueo de la transformacion neoplasica de celulas inducida por oncogenes ras. - Google Patents

Uso de bifosfonatos para la fabricacion de un medicamento para el bloqueo de la transformacion neoplasica de celulas inducida por oncogenes ras.

Info

Publication number
ES2080452T3
ES2080452T3 ES92309185T ES92309185T ES2080452T3 ES 2080452 T3 ES2080452 T3 ES 2080452T3 ES 92309185 T ES92309185 T ES 92309185T ES 92309185 T ES92309185 T ES 92309185T ES 2080452 T3 ES2080452 T3 ES 2080452T3
Authority
ES
Spain
Prior art keywords
biphosphonates
manufacture
block
medicinal product
cells induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309185T
Other languages
English (en)
Inventor
Scott A Biller
Mairiano Barbacid
Eric M Gordon
David R Magnin
Chester A Meyers
Veeraswamy Manne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2080452T3 publication Critical patent/ES2080452T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UN METODO PARA BLOQUEAR O EVITAR LA PRENILACION DE LA CUBIERTA CAAX QUE CONTIENE PROTEINAS QUE INCLUYEN PRODUCTOS DEL ONCOGENE RAS EVITANDO Y/O TRATANDO TUMORES RELACIONADOS CON EL RAS, EL METODO INCLUYE EL PASO DE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UN INHIBIDOR DE LA TRANSFERASA PRENIL DE LA PROTEINA QUE ES UN BISFOSFONATO O UN ANALOGO DEL MISMO.
ES92309185T 1991-10-11 1992-10-08 Uso de bifosfonatos para la fabricacion de un medicamento para el bloqueo de la transformacion neoplasica de celulas inducida por oncogenes ras. Expired - Lifetime ES2080452T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77491191A 1991-10-11 1991-10-11

Publications (1)

Publication Number Publication Date
ES2080452T3 true ES2080452T3 (es) 1996-02-01

Family

ID=25102663

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309185T Expired - Lifetime ES2080452T3 (es) 1991-10-11 1992-10-08 Uso de bifosfonatos para la fabricacion de un medicamento para el bloqueo de la transformacion neoplasica de celulas inducida por oncogenes ras.

Country Status (8)

Country Link
EP (1) EP0537008B1 (es)
JP (1) JPH05201869A (es)
AT (1) ATE129407T1 (es)
CA (1) CA2080158A1 (es)
DE (1) DE69205657T2 (es)
DK (1) DK0537008T3 (es)
ES (1) ES2080452T3 (es)
GR (1) GR3018754T3 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451401A (en) * 1993-09-29 1995-09-19 The Procter & Gamble Company Diphosphonic acid esters as tartar control agents
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
GB9422814D0 (en) * 1994-11-11 1995-01-04 Medinnova Sf Chemical method
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
AU717165B2 (en) 1996-04-11 2000-03-16 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
CA2334645A1 (en) * 1998-06-24 1999-12-29 Hassan Jomaa Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism
CA2352486A1 (en) * 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
CA2451881A1 (fr) 2001-07-16 2003-01-30 Universite Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018470A1 (en) * 1989-07-17 1991-01-17 Scott Adams Biller Phosphorus-containing squalene synthetase inhibitors and method
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤

Also Published As

Publication number Publication date
GR3018754T3 (en) 1996-04-30
CA2080158A1 (en) 1993-04-12
JPH05201869A (ja) 1993-08-10
DE69205657D1 (de) 1995-11-30
ATE129407T1 (de) 1995-11-15
DK0537008T3 (da) 1995-12-04
EP0537008A1 (en) 1993-04-14
DE69205657T2 (de) 1996-06-13
EP0537008B1 (en) 1995-10-25

Similar Documents

Publication Publication Date Title
ES2080452T3 (es) Uso de bifosfonatos para la fabricacion de un medicamento para el bloqueo de la transformacion neoplasica de celulas inducida por oncogenes ras.
ES2075630T3 (es) Uso de inhibidores de la proteina-farnesil transferasa para la preparacion de un medicamento para bloquear la transformacion neoplastica de celulas inducidas por oncogenes ras.
IS1805B (is) Aðferð til að framleiða nýjar peptíðafleiður sem eru þrombíntálmar
ES2031822T3 (es) Un procedimiento para preparar una composicion farmaceutica con propiedades inhibidoras de la renina.
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
ES2137963T3 (es) Utilizacion del acido carnosico por sus propiedades anticarcinogenas y antiviricas.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ES2153394T3 (es) Medicamento que contiene la subunidad p40 de interleuquina-12.
AU6165894A (en) Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
HUT70758A (en) Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters and their pharmaceutical acceptable salts
DE69302439D1 (de) Topisches Präparat zur Verhütung oder Behandlung der Akne Vulgaris
ES2073324T3 (es) Empleo de soportes intumescentes para vidrios protectores contra incendios.
DE3686022D1 (de) Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
BR9104888A (pt) Inibidor e processo para inibicao de polimerizacao de um composto vinila
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
ES2086359T3 (es) R(-)-1-(5-hidroxihexil)-3-metil-7-propilxantina, procedimiento para su preparacion y medicamentos que contienen este compuesto.
ATE191847T1 (de) Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
IT1283697B1 (it) Procedimento di trattamento di oggetti a mezzo di un liquido volatile infiammabile
NO941259D0 (no) Anvendelse av en trietanolamin-produktblanding
ATE163856T1 (de) Verwendung eines direkten inhibitors von thrombin zur herstellung eines arzneimittels mit thrombolytischer aktivität
GB2272535B (en) Manufacture of alignment marks for holographic lithography
ES2088135T3 (es) Inhibicion de agregacion de particulas que contienen farmacos.
DE59203472D1 (de) Verwendung von dl-valin, dessen estern und/oder salzen zur bekämpfung von kopfschuppen.
DE69201818T2 (de) Verfahren zur linearen Dikarbonylierung von difunktionellisierten Butenen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 537008

Country of ref document: ES